We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

99 hedge funds and large institutions have $36.1M invested in Protalix BioTherapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 9

70% more call options, than puts

Call options by funds: $651K | Put options by funds: $383K

40% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 20

35% more capital invested

Capital invested by funds: $26.8M → $36.1M (+$9.28M)

19% more funds holding

Funds holding: 83 → 99 (+16)

2.13% more ownership

Funds ownership: 18.53% → 20.66% (+2.1%)

Holders
99
Holders Change
+16
Holders Change %
+19.28%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
28
Reduced
20
Closed
9
Calls
$651K
Puts
$383K
Net Calls
+$268K
Net Calls Change
+$287K

Top Buyers

Rank Fund Capital Flow
1
MCO
MAK Capital One
New York
+$8.79M
2
PFS
Prospera Financial Services
Texas
+$1.04M
3
State Street
State Street
Massachusetts
+$962K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$665K
5
Morgan Stanley
Morgan Stanley
New York
+$421K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$5.31M
2
Citadel Advisors
Citadel Advisors
Florida
-$788K
3
Jane Street
Jane Street
New York
-$676K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$378K
5
Barclays
Barclays
United Kingdom
-$243K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$6.42K +$3.29K +1,324 +81%
Fidelity Investments
77
Fidelity Investments
Massachusetts
$6.3K +$1.46K +590 +25%
National Bank of Canada
78
National Bank of Canada
Quebec, Canada
$4.36K +$4.96K +2,000 New
Carson Wealth (CWM LLC)
79
Carson Wealth (CWM LLC)
Nebraska
$3.33K +$3.3K +1,331 +656%
IRAG
80
Investment Research & Advisory Group
Georgia
$2.17K – – –
GI
81
GAMMA Investing
California
$1.04K +$308 +124 +35%
SCM
82
Sterling Capital Management
North Carolina
$983 – – –
Osaic Holdings
83
Osaic Holdings
Arizona
$651 -$2.23K -900 -75%
AWM
84
Activest Wealth Management
Florida
$651 – – –
FDCDDQ
85
Federation des caisses Desjardins du Quebec
Quebec, Canada
$543 – – –
CMBA
86
C.M. Bidwell & Associates
Hawaii
$512 +$586 +236 New
YDMI
87
Y.D. More Investments
Israel
$477 – – –
RFP
88
Root Financial Partners
California
$278 +$318 +128 New
Northwestern Mutual Wealth Management
89
Northwestern Mutual Wealth Management
Wisconsin
$217 +$248 +100 New
AAP
90
Arax Advisory Partners
Colorado
$120 +$40 +16 +41%
MCM
91
MAI Capital Management
Ohio
$63 +$72 +29 New
AF
92
Allworth Financial
California
$57 +$65 +26 New
EP
93
Essential Partners
California
$56 +$65 +26 New
PNC Financial Services Group
94
PNC Financial Services Group
Pennsylvania
$43 – – –
RIL
95
Rothschild Investment LLC
Illinois
$33 +$37 +15 New
EWA
96
EverSource Wealth Advisors
Alabama
$24 +$27 +11 New
TWD
97
True Wealth Design
Ohio
$24 +$27 +11 New
IA
98
IFP Advisors
Florida
$7 +$7 +3 New
SS
99
SBI Securities
Japan
$2 – – –
Citadel Advisors
100
Citadel Advisors
Florida
– -$788K -317,628 Closed
1 2 3
4
5

PLX Hedge Fund Activity: Q1 2026 in Review

99 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2026, worth a combined $36.1M — up 35% from $26.8M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PLX positions and 9 closed out — a net gain of 18 holders — while 28 added to existing stakes and 20 trimmed.

The largest buyer was MAK Capital One, opening a new position worth an estimated $8.79M. The largest seller was Opaleye Management, cutting an estimated $5.31M.

  • 99 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2026, up from 83 in Q4 2025.
  • Funds reported $36.1M of Protalix BioTherapeutics stock for Q1 2026, up 35% quarter-over-quarter.
  • 27 funds opened new Protalix BioTherapeutics positions in Q1 2026 and 9 closed out, a net change of +18 holders.
  • The largest Protalix BioTherapeutics buyer in Q1 2026 was MAK Capital One, an estimated $8.79M added.
  • The largest Protalix BioTherapeutics seller in Q1 2026 was Opaleye Management, an estimated $5.31M sold.

Based on aggregated 13F filings for Q1 2026.